CD8A and neoplasm: Despite this level of attenuation, ADXS31-164 was able to disrupt immune tolerance toward the HER2/neu self-antigen, eliciting strong T-cell responses in experimental animal tumor models that resulted in a reduction in regulatory T cells (Tregs), an increase in the CD8+/Treg ratio, and a reduction in tumor growth [17].